"Finding the right FIT": Rural patient preferences for fecal immunochemical test (FIT) characteristics

Journal of the American Board of Family Medicine

Volumn 30, Issue 5, 2017, Pages 632-644

  Pham, Robyn ^a,b   Cross, Suzanne ^b,c   Fernandez, Bianca ^b,d   Corson, Kathryn ^b   Dillon, Kristen ^b,e   Yackley, Coco ^b,c   Davis, Melinda M ^a,b,f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Community Health Advocacy and Research Alliance ^*  (United States)

^c Columbia Gorge Health Council ^*  (United States)

^d Nuestra Comunidad Sana   (United States)

^e Pacific Source Columbia Gorge CCO   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Colorectal Neoplasms; Early Detection of Cancer; Occult Blood; Patient Preference; Treatment Outcome

Indexed keywords

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMMUNITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CULTURAL SENSITIVITY; DATA COLLECTION METHOD; DIAGNOSTIC TEST ACCURACY STUDY; ENGLISH (LANGUAGE); FEAR; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEALTH CARE COST; HISPANIC; HUMAN; INTROSPECTION; MALE; METHODOLOGY; OCCULT BLOOD TEST; OCCULT BLOOD TEST KIT; PACKAGING; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT PREFERENCE; PATIENT SELECTION; PERSONAL EXPERIENCE; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; QUESTIONNAIRE; RURAL AREA; RURAL POPULATION; SEMI STRUCTURED INTERVIEW; SENSITIVITY AND SPECIFICITY; SEQUENTIAL EXPLANATORY MIXED METHODS DESIGN; SPANISH (LANGUAGE); COLORECTAL TUMOR; DEVICES; EARLY CANCER DIAGNOSIS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PROCEDURES; SPECIMEN HANDLING; STATISTICS AND NUMERICAL DATA; UNITED STATES;

COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PATIENT PREFERENCE; RURAL POPULATION; SPECIMEN HANDLING; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 85029722871     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2017.05.170151     Document Type: Article

References (57)

1. Colorectal Cancer Facts & Figures 2014-2016. Atlanta, GA: American Cancer Society; 2014.
2. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: A decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149: 659-69.
3. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. preventive services task force. Ann Intern Med 2008;149:638-58.
4. Morbidity, and Mortality Weekly Report (MMWR). Vital signs: Colorectal cancer screening test use- United States, 2012. MMWR Morb Mortal Wkly Rep 2013;62:881-8.
5. Society AC. Colorectal Cancer Facts & Figures 2017-2019. Atlanta, GA: American Cancer Society; 2017.
6. 80% by 2018. 2016. Available from: http://nccrt.org/ tools/80-percent-by-2018. Accessed on January 23, 2017.
7. Sabatino SA, White MC, Thompson TD, et al. Cancer screening test use-United States, 2013. MMWR Morb Mortal Wkly Rep 2015;64:464-8.
8. Cole AM, Jackson JE, Doescher M. Urban-rural disparities in colorectal cancer screening: Cross-sectional analysis of 1998-2005 data from the Centers for Disease Control's Behavioral Risk Factor Surveillance Study. Cancer Med 2012;1:350-6.
9. Davis MM, Pham R, et al. Geographic and popluation- level disparities in colorectal cancer screening: A multilevel analysis if medicaid and commercial claims data. Prev Med 2017;101:44-52.
10. Gupta S, Sussman DA, Doubeni CA, et al. Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst 2014;106(4):dju032.
11. Lieberman D, Ladabaum U, Cruz-Correa M, et al. Screening for colorectal cancer and evolving issues for physicians and patients: A review. JAMA 2016;316:2135-45.
12. United States Preventive Services Task Force (USPSTF). Final Update Summary: Colorectal Cancer: Screening. 2016.
13. Honein-AbouHaidar GN, Kastner M, Vuong V, et al. Benefits and barriers to participation in colorectal cancer screening: a protocol for a systematic review and synthesis of qualitative studies. BMJ Open 2014;4(2):e004508.
14. Mackie A. Moving from guaiac faecal occult blood test (gFOBT) to a faecal immunochemical test for haemoglobin (FIT) in the bowel screening programme: A consultation. 2015.
15. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58(3):130-60.
16. Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 2006;145:880-6.
17. Hoffman RM, Espey D, Rhyne RL. A public-health perspective on screening colonoscopy. Expert Rev Anticancer Ther 2011;11:561-9.
18. Panteris V, Haringsma J, Kuipers EJ. Colonoscopy perforation rate, mechanisms and outcome: From diagnostic to therapeutic colonoscopy. Endoscopy 2009;41:941-51.
19. Schoenberg NE, Eddens K, Jonas A, et al. Colorectal cancer prevention: Perspectives of key players from social networks in a low-income rural US region. Int J Qual Stud Health Well-being 2016;11(1):30396.
20. Bowyer HL, Vart G, Kralj-Hans I, et al. Patient attitudes towards faecal immunochemical testing for haemoglobin as an alternative to colonoscopic surveillance of groups at increased risk of colorectal cancer. J Med Screen 2013;20(3):149-56.
21. Ruffin MT 4th, Creswell JW, Jimbo M, Fetters MD. Factors influencing choices for colorectal cancer screening among previously unscreened African and Caucasian Americans: Findings from a triangulation mixed methods investigation. J Community Health 2009;34(2):79-89.
22. Green BB, Coronado GD, Devoe JE, et al. Navigating the murky waters of colorectal cancer screening and health reform. Am J Public Health 2014;104: 982-6.
23. Inadomi JM, Vijan S, et al. Adherence to colorectal cancer screening: A randomized clinical trial of competing strategies. Arch Intern Med 2012;172: 575-82.
24. Shokar NK, Carlson CA, Weller SC. Informed decision making changes test preferences for colorectal cancer screening in a diverse population. Ann Fam Med 2010;8:141-50.
25. DeBourcy A, Lichtenberger S, Felton S, et al. Community- based preferences for stool cards versus colonoscopy in colorectal cancer screening. J Gen Intern Med 2008;23:169-74.
26. Gupta S, Halm EA, Rockey DC, et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: A randomized clinical trial. JAMA Intern Med 2013;173:1725-32.
27. Allison JE, Fraser CG, Halloran SP, et al. Population screening for colorectal cancer means getting FIT: The past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver 2014;8:117-30.
28. Vart G, Banzi R, Minozzi S. Comparing participation rates between immunochemical and guaiac fae-cal occult blood tests: A systematic review and metaanalysis. Prev Med 2012;55:87-92.
29. Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: What clinicians and colorectal cancer screening programme organisers need to know. Gut 2015;64:1327-37.
30. World Endoscopy Organization. FIT for Screening. 2017. Available from: http://www.worldendo.org/ about-us/committees/colorectal-cancer-screening/ ccs-testpage2-level4/fit-for-screening. Accessed Jan 31, 2017.
31. Chubak J, Bogart A, Fuller S, et al. Uptake and positive predictive value of fecal occult blood tests: A randomized controlled trial. Prev Med 2013;57: 671-8.
32. Daly JM, Bay CP, Levy BT. Evaluation of fecal immunochemical tests for colorectal cancer screening. J Prim Care Community Health 2013;4:245-50.
33. Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical tests for colorectal cancer: Systematic review and meta-analysis. Ann Intern Med 2014;160:171.
34. Creswell JW, Plano Clark VL. Designing and Conducting Mixed Methods Research. 2nd ed. Thousand Oaks, CA: Sage Publications, Inc; 2011.
35. Creswell JW, Klassen AC, Plano Clark VL, et al. Best practices for mixed methods research in the health sciences. Office of Behavioral and Social Sciences Research (OBSSR); 2011.
36. Nay B, Knivila K. Oregon's Coordinated Care Organizations-Health system transformation or managed care revisited? Insights. Williamette Management Associates; 2013.
37. OregonLaws.org. 2015 ORS 414.627 Community Advisory Councils. 2015.
38. McConnell K. Oregon's Medicaid coordinated care organizations. JAMA 2016;315:869-70.
39. McConnell KJ, Renfro S, Chan BK, et al. Early performance in Medicaid accountable care organizations: A comparison of Oregon and Colorado. JAMA Intern Med 2017;177(4):538-545.
40. Oregon Health Authority. CCO Metrics. 2013.
41. Oregon Health Authority. Oregon's health system transformation: CCO metrics 2015 final report. 2016.
42. Columbia Gorge Regional Community Health Assessment [PDF]. December 2013.
43. Worthley DL, Cole SR, Mehaffey S, et al. Participant satisfaction with fecal occult blood test screening for colorectal cancer. J Gastroenterol Hepatol 2007;22:142-3.
44. Deutekom M, van Rossum LG, van Rijn AF, et al. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: The patient perspective. Scand J Gastroenterol 2010;45: 1345-9.
45. Neergaard MA, Olesen F, Andersen RS, et al. Qualitative description-The poor cousin of health research? BMC Med Res Methodol 2009;9(1):52.
46. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health 2000;23:334-40.
47. File Update Summary: Colorectal Cancer: Screening. July 2015. Available from: https://www. uspreventiveservicestaskforce.org/Page/Document/ UpdateSummaryFinal/colorectal-cancer-screening.
48. Cole SR, Young GP, Esterman A, et al. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003;10:117-22.
49. Gordon NP, Green BB. Factors associated with use and non-use of the fecal immunochemical test (fit) kit for colorectal cancer screening in response to a 2012 outreach screening program: A survey study. BMC Pub Health 2015;15(1):546.
50. O'Sullivan I, Orbell S. Self-sampling in screening to reduce mortality from colorectal cancer: A qualitative exploration of the decision to complete a faecal occult blood test (FOBT). J Med Screen 2004;11: 16-22.
51. Coronado GD, Sanchez J, Petrik A, et al. Advantages of wordless instructions on how to complete a fecal immunochemical test: Lessons from patient advisory council members of a federally qualified health center. Journal Cancer Educ 2014;29:86-90.
52. Chiang TH, Lee YC, Tu CH, et al. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ 2011;183:1474-81.
53. Cheng TI, Wong JM, Hong CF, et al. Colorectal cancer screening in asymptomaic adults: Comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. J Formos Med Assoc 2002;101:685-90.
54. Benefits. The new recommended technology for occult blood detection to aid in colorectal cancer screening. Available from: http://hemosure.com/ sales/benefits/. Accessed March 23, 2017.
55. Smith A, Young GP, Cole SR, et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 2006;107:2152-9.
56. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: Update on performance characteristics. J Natl Cancer Inst 2007;99:1462-70.
57. Ko CW, Dominitz JA, Nguyen TD. Fecal occult blood testing in a general medical clinic: Comparison between guaiac-based and immunochemicalbased tests. Am J Med 2003;115:111-4.